established a novel IGF2BP1/CDC5L pathogenic axis in multiple myeloma (MM), where BTYNB effectively suppresses the expression of CDC5L, thereby inhibiting MM progression (206). This evidence concerns the gene CDC5L and plasma cell myeloma.